reSET-O is an FDA-cleared Prescription Digital Therapeutic (PDT) for the treatment of Opioid Use Disorder (OUD). It is a 12-week (84-day) software application intended to be used as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for adult patients (18 years or older) under the supervision of a clinician.
The software is delivered via a mobile application downloaded to the patient's smartphone or tablet. It is built on the principles of the Community Reinforcement Approach (CRA) to Cognitive Behavioral Therapy (CBT).
Key Features and Capabilities:
- Interactive CBT Modules: Delivers self-paced psychoeducational therapeutic lessons designed to help patients learn new skills and reinforce abstinence.
- Contingency Management (CM): An evidence-based rewards system that provides incentives, often in the form of digital retail gift cards, for completing modules and having negative drug screens (managed by the provider).
- Medication Adherence: Includes daily reminders to take buprenorphine medication.
- Self-Reporting Tools: Allows patients to track and report substance use, cravings, and triggers with a tap, providing real-time data.
- Clinician Dashboard: A web-based interface that allows healthcare providers to remotely monitor patient engagement, progress, self-reported data, and buprenorphine adherence, facilitating more informed in-person sessions.
The primary goal of reSET-O is to increase patient retention in outpatient treatment, which clinical trials have shown it does significantly when compared to treatment as usual.